Fig. 4

Fargesin reprograms macrophages from M1 to M2 subtype via p38/ERK MAPK and p65/NF-κB pathways. a–f Immunostaining and quantitative analysis of nuclear localized cells for ERK, p38, and p65 in Raw264.7 cells treated with LPS (1 μg/mL) for 30 min after administering vehicle or fargesin for 3 h (n = 4). Scale bar, 50 μm. Higher magnification is shown on the top right. Scale bar, 100 μm. g Western blot results for p-p65, p65, p-ERK, ERK, p-p38, and p38 in Raw264.7 cells treated with LPS and co-treated with or without fargesin (n = 4)